We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The new Bimzelx administration and dosage is available ...

Bimzelx is a type of medicine called a monoclonal antibody. Monoclonal antibodies are human-made antibodies created in the lab to mimic antibodies in the body. Bimzelx works by blocking two naturally ...

Credit: UCB The new presentations allow for single administration for certain indications. The new presentations allow for single administration to treat plaque psoriasis, hidradenitis suppurativa, ...

(RTTNews) - UCB announced that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX is now available. These are in addition to the 1 mL device administration ...

After strutting its stuff against blockbusters in three head-to-head psoriasis trials, UCB’s Bimzelx has conquered another powerhouse product—AbbVie’s Skyrizi—in psoriatic arthritis (PsA). A phase 3b ...

Please provide your email address to receive an email when new articles are posted on . Bimzelx (bimekizumab-bkzx) is the first and only interleukin 17A and 17F inhibitor approved in this indication.

Bimzelx (bimekizumab-bkzx) is a prescription drug used in certain adults to treat plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and ...

Approval is supported by data from the two Phase 3 studies, BE HEARD I and BE HEARD II, in which BIMZELX ® (bimekizumab-bkzx) improved the signs and symptoms of disease vs. placebo at Week 16, which ...

Bimzelx is a brand-name biologic medication used to treat plaque psoriasis and other conditions by blocking specific immune system proteins that cause inflammation. More common side effects of Bimzelx ...

ATLANTA, March 11, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive topline data from the BE BOLD trial assessing BIMZELX® (bimekizumab) versus SKYRIZI® ...